EPO and Huntington disease: The outcomes showed that most chronic, stable HD patients can maintain stable hematocrit and Hb concentrations at once weekly SC EPO doses that are one-third of the required weekly IV dose thereby lending support to its safety and efficacy. Patient safety, serum biochemistry, blood pressure and red blood cell indices were also monitored during the study, with no significant differences in any variable between the control and experimental group.